TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05748119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo
Study: NCT04722601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
Study: NCT04994600

Intervention type: OTHER
Intervention: Reduces number of question items
Description: The number of alarm fatigue questions are reduced to about 15 in the CFA_2nd_phase group.
Study: NCT04907903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Description: Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
Study: NCT05959031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kTMP
Description: a new non-invasive brain stimulation tool

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham kTMP
Description: a new non-invasive brain stimulation tool with sham setting selected
Study: NCT05894044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Russian current 10%
Description: Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aussie current 10%
Description: Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed current 500 µs phase
Description: Pulsed current, modulated in 50 Hz, 500 µs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed current 200 µs phase
Description: Pulsed current, modulated in 50 Hz, 200 µs
Study: NCT05155657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus low dose UCMSCs treatment
Description: Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10\^6 UCMSCs/kg body)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus medium dose UCMSCs treatment
Description: Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10\^6 UCMSCs/kg body)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus high dose UCMSCs treatment
Description: Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10\^6 UCMSCs/kg body)
Study: NCT06335498

Intervention type: DEVICE
Intervention: ECG co-measurement
Description: Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG

Intervention type: DEVICE
Intervention: ECG co-measurement
Description: Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG

Intervention type: DEVICE
Intervention: Periodic ECG triggered measurement
Description: Subject triggers AFGen1 to perform an extended measurement during wear period
Study: NCT05508685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT and Cognitive Reassessment
Description: Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT group
Description: Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emotional regulation strategy group
Description: Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
Study: NCT04910074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dummy LLLT
Description: The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
Study: NCT04722601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral form of azacitidine (a standard chemotherapy drug).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral form of azacitidine (a standard chemotherapy drug).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral form of azacitidine (a standard chemotherapy drug).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral form of azacitidine (a standard chemotherapy drug).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral form of azacitidine (a standard chemotherapy drug).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral form of azacitidine (a standard chemotherapy drug).
Study: NCT06224322

Intervention type: OTHER
Intervention: Assesment Scale
Description: Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
Study: NCT04024293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldfish (GF)
Description: The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
Study: NCT04899817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron
Description: The drug is given after induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: The drug is given after induction of general anesthesia
Study: NCT06105567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training given according to the health promotion model by applying the Philips 66 technique
Description: The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
Study: NCT04569695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
Study: NCT05457556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT05941858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard cessation treatments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard cessation treatments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to WaQi program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Receive access to WaQi program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Receive referral for NRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement
Description: Receive referral for NRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Practice Tai Chi

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Practice Tai Chi
Study: NCT05698121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapriXpress
Description: The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
Study: NCT05457556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT04981977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Transitions Intervention
Description: CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Transitions Intervention and Peer Support
Description: The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
Study: NCT04083001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTR4132MD
Description: According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours.
Study: NCT05457556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given intravenously (IV)
Study: NCT05873361

Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
Study: NCT05457556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT05818748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: virtual reality distraction
Study: NCT05457556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical Hematopoietic Cell Transplantation
Description: Undergo haploHCT
Study: NCT05061576

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care advice on physical activity
Description: Oral advice on exercise from a physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured advice on physical activity
Description: A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
Study: NCT06301061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equistasi®
Description: Four devices will be attached to the skin according the indication of the investigators for 6 hours/day every day except Thursday and Sunday

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Four devices similar to the active one but not able to deliver the microvibration will be applied to the patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin; Pregabalin; Duloxetine; Amitriptyline
Description: Patients will be treated with drugs (gabapentinoids, Serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressants, opioids) according to guidelines.
Study: NCT04661033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Study: NCT05276674

Intervention type: DEVICE
Intervention: ZNN Bactiguard Retrograde Femoral Nail
Description: Femoral fracture internal fixation.
Study: NCT05901610

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Episodic Future Thinking
Description: Participants will generate descriptions of vivid positive future events.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Episodic Future Thinking
Description: Participants will generate descriptions of vivid positive future events.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Episodic Thinking
Description: Participants will generate descriptions of vivid positive past events.

Intervention type: DEVICE
Group type: OTHER
Intervention: Low-intensity Focused Ultrasound
Description: A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.

Intervention type: DEVICE
Group type: OTHER
Intervention: Low-intensity Focused Ultrasound
Description: A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Low-intensity Focused Ultrasound
Description: All of the same actions done during LIFU will be performed, but the device will be inactive.
Study: NCT05439980

Intervention type: OTHER
Intervention: Knowledge questionnaire
Description: Completion of a questionnaire at baseline

Intervention type: OTHER
Intervention: Knowledge questionnaire
Description: Completion of a questionnaire at baseline

Intervention type: OTHER
Intervention: Knowledge questionnaire
Description: Completion of a questionnaire at baseline

Intervention type: OTHER
Intervention: Focus groups
Description: structured interviews